
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
Read about how we helped The Clinician increase users to their website by 85%, new users by 92%, and sessions by 94%






